Advertisements

Bismatrol Maximum Strength

Quick links to important sections

Bismatrol Maximum Strength

Advertisements
Advertisements

Method of action: Antacid, Bismuth Containing

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Bismatrol Maximum Strength

Property Description
Active Ingredient Bismuth Subsalicylate
Form Oral Suspension, Chewable Tablets, Caplets
Pharmacological Class Antidiarrheal agent, Anti-secretory agent
Common Use Relief of general digestive upset
Origin Synthetic derivative

What Type of Medicine is Bismatrol Maximum Strength and Its Classification?

Bismatrol Maximum Strength is a widely available, over-the-counter (OTC) medication whose sole active component is Bismuth Subsalicylate. It is categorized as an antidiarrheal agent and an anti-secretory agent, signifying its primary function in addressing temporary gastrointestinal upset. The medication is a synthetic derivative, specifically a salt complex of the trivalent bismuth cation and salicylic acid. This unique composition, combining bismuth and salicylate, is recognized for symptomatic relief in typical use scenarios. The active ingredient plays a role in the symptomatic treatment of nonspecific diarrheal conditions.


Composition, Formulation, and Maximum Strength Designation

The formulation is defined by its core ingredient, Bismuth Subsalicylate, and is administered via the oral route in multiple dosage forms, including a flavored Oral Suspension (liquid medication), Chewable Tablets, and Caplets. This variety in preparation type offers flexibility in patient use. The key differentiating feature of this specific brand formulation is the "Maximum Strength" designation, which is a formulation characteristic generally denoting a higher concentration of the active component per dose unit compared to the product’s standard versions.


Core Purpose: How Does Bismatrol Generally Help?

The general purpose of Bismatrol Maximum Strength is to provide relief for overall, temporary digestive upset through its recognized physiological actions. The medication acts locally in the gastrointestinal tract, where the bismuth component creates a temporary, cytoprotective coating to soothe irritated mucosal surfaces. Simultaneously, the salicylate component contributes an anti-secretory effect that helps inhibit the excessive movement of fluid into the bowel. This action assists in reducing the amount of water secreted into the intestines. This combined mechanism enables the product to help firm loose stools and calm the digestive system by simultaneously addressing irritation and fluid imbalance.

Regulatory References

  1. National Institutes of Health (NIH) confirms
Advertisements

What side effects are possible with Bismatrol Maximum Strength?

Possible Side Effects and Safety Information

This section outlines the officially documented safety profile of Bismatrol Maximum Strength, strictly based on regulatory health authority documents.

Serious Safety Restrictions and Warnings

Reye's Syndrome Risk

Official regulatory labeling includes a mandatory warning regarding the risk of Reye's syndrome, a rare but potentially fatal condition. Use of this medication is strictly restricted in children and teenagers who are recovering from chickenpox or flu-like symptoms.

Salicylate Toxicity (Salicylism)

Individuals must stop using this product and consult a health professional if symptoms of salicylate toxicity occur, specifically ringing in the ears (tinnitus) or hearing loss. These symptoms may indicate excessively high levels of the active ingredient in the body.

Contraindications and Use Limitations

This medication must not be used by individuals with a stomach ulcer, a bleeding problem, or bloody or black stool. It is also contraindicated for anyone with a known allergy or hypersensitivity to salicylates, including aspirin.

Documented Adverse Reactions

Adverse reactions associated with the medication are primarily gastrointestinal. The most commonly noted effects include:

  • Darkening of the Tongue
  • Darkening/Black Stool

These changes are temporary, harmless, and typically reversible upon discontinuation of the product. Less common documented effects include nausea, vomiting, and constipation.

Population-Specific Safety Notes

Regulatory information requires caution for specific patient groups:

  • Pregnant Patients: Use is not recommended during the last trimester (after 20 weeks) of pregnancy.
  • Drug Interactions: Consultation with a health professional is necessary before combining this product with other medications, particularly anticoagulants (blood thinners) and medications for diabetes or gout.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for Bismuth Subsalicylate is defined by the resulting Salicylate Toxicity (Salicylism) and the potential for severe systemic outcomes.

Overdose Scope

Property Description (Strictly Regulatory-Derived)
Documented overdose presentations Primarily Salicylate Toxicity signs, including tinnitus (ringing in ears), diminished hearing, hyperventilation (rapid, deep breathing), confusion, severe drowsiness, and vomiting. Chronic overdose may lead to bismuth neurotoxicity signs like tremors and myoclonus.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Renal system, and Metabolic system (leading to acid-base disturbances).
Dose-related or exposure-related factors (if applicable) Toxicity is generally associated with elevated plasma salicylate concentrations. Chronic, excessive exposure can lead to the accumulation of bismuth, resulting in neurotoxicity.
Population-specific overdose notes (if applicable) The elderly or frail may be particularly vulnerable to salicylism. The risk of Reye's syndrome in children and teenagers with flu-like symptoms or chickenpox is a documented risk requiring urgent attention.
Emergency-response statements (as written in official documents) Seek emergency help at once or immediately contact a Poison Control Center.
When immediate medical help is required (label-derived phrasing only) Immediate contact with emergency services is required if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Description (Strictly Regulatory-Derived)
Severity classification (as defined in official documents) Potential for severe and life-threatening outcomes, including metabolic acidosis, renal failure, convulsions, and coma.
Regulatory basis (EMA / FDA / etc.) Information derived from FDA Prescribing Information, NIH MedlinePlus, and MHRA/EMA Summary of Product Characteristics (SmPC) for Bismuth Subsalicylate.
Overdose-context constraints (as defined in official documents) No specific antidote is known; management requires symptomatic and supportive treatment.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to serious acid-base disturbances, including metabolic acidosis, necessitating monitoring of the patient's acid-base status.
  • Supportive procedures such as gastric lavage, administration of activated charcoal, and in severe cases, haemodialysis, are officially described for management.
  • Monitoring of plasma salicylate concentrations is an essential procedural requirement, with concentrations exceeding a specific threshold indicating toxicity.

Connection to the overall overdose profile:

Governmental regulatory documents define the overdose profile by listing the expected Salicylate Toxicity manifestations and detailing the severe systemic and CNS outcomes that may arise, such as metabolic acidosis and convulsions. This officially established severity forms the basis for the non-negotiable instruction to seek emergency help at once and outlines the necessary supportive medical procedures required for hospital management.

Advertisements

Therapeutic Uses of Bismatrol Maximum Strength

Main Uses of Bismatrol Maximum Strength

Bismatrol Maximum Strength is an over-the-counter antidiarrheal and antacid medication. It contains a higher concentration of the active ingredient, bismuth subsalicylate, compared to regular strength formulations. It is primarily used to manage gastrointestinal discomfort and symptoms associated with digestive upset.

Relief of Diarrhea

The primary use of Bismatrol Maximum Strength is the control of diarrhea. It helps reduce the frequency of bowel movements and improves stool consistency. This includes the management of:

  • Acute Diarrhea: General episodes of sudden-onset diarrhea.
  • Traveler's Diarrhea: Digestive distress often caused by consuming contaminated food or water during travel.

Management of Indigestion and Stomach Upset

Bismatrol Maximum Strength is also used to alleviate various symptoms of indigestion. By coating the stomach lining and neutralizing certain digestive triggers, it helps relieve:

  • Heartburn: The burning sensation in the chest or throat caused by acid reflux.
  • Indigestion (Dyspepsia): General discomfort or pain in the upper abdomen.
  • Nausea: Feelings of stomach sickness or the urge to vomit.
  • Gas and Belching: Relief from pressure and bloating associated with excess gas.
  • Fullness: The sensation of being uncomfortably full after eating.

Benefits of the Maximum Strength Formula

The maximum strength variant provides a more potent dose of bismuth subsalicylate per serving. This is intended for individuals who require more intensive symptom management for acute gastrointestinal issues.

Protective Action

Bismuth subsalicylate works through several mechanisms. It possesses anti-secretory properties that help reduce fluid loss during diarrhea. Additionally, it exhibits mild antibacterial properties and acts as a protective coating for the mucosal lining of the esophagus and stomach, which helps mitigate the irritation caused by stomach acid.

Regulatory References

  1. FDA DailyMed label for Bismuth Subsalicylate
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Bismatrol Maximum Strength?

This section describes the population eligibility rules for Bismatrol Maximum Strength (Bismuth Subsalicylate) based strictly on official regulatory labeling.

Contraindicated and Restricted Populations

Eligibility Status Population/Condition
Contraindicated Individuals with salicylate allergy (including aspirin).
Individuals with a current ulcer, a bleeding problem, or bloody/black stools.
Children and teenagers with or recovering from chickenpox or flu-like symptoms (due to Reye's syndrome risk).
Conditional Use Individuals who are pregnant or breastfeeding (must consult a doctor).
Individuals with kidney disease, liver disease, diabetes, or gout (must consult a doctor).
Not Recommended Children under 12 years of age.

Age-Related Eligibility

Use is officially permitted for adults and teenagers 12 years of age and older who have no documented contraindications. Eligibility for use in all populations is subject to adherence to these regulatory restrictions, which are primarily related to the presence of the salicylate component and the risk of gastrointestinal bleeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Bismatrol Maximum Strength (Bismuth Subsalicylate) outlines several important interaction patterns related to both its salicylate and bismuth components.

Contraindicated and High-Risk Combinations

Co-administration with other salicylate-containing products, including aspirin, is officially prohibited. This restriction is due to the increased risk of reaching toxic salicylate levels in the body. Additionally, use is strictly prohibited in children and teenagers who have or are recovering from chickenpox or flu-like symptoms because the salicylate component is associated with the risk of Reye’s syndrome.

Documented Interactions with Medicinal Products

Interacting Product Category Regulatory Concern
Anticoagulants (e.g., Warfarin) Salicylate component may potentiate the effect, increasing bleeding risk.
Tetracycline Antibiotics Bismuth component can reduce systemic absorption of the antibiotic.
Uricosuric Agents (for Gout) Salicylate component may decrease the intended efficacy of these medicines.
Oral Anti-diabetic Medications Official caution is advised regarding potential interference with the action of these medicines.

Required Timing Separation

To mitigate the reduced absorption of tetracycline antibiotics, official regulatory documents require that Bismatrol Maximum Strength be administered at least 1 hour before or 3 hours after the antibiotic.

Population-Specific Notes

Interaction-related risks, such as potential toxicity, are officially noted as a concern for elderly patients and individuals with renal impairment due to the body’s reduced ability to clear the medicine's components.

Advertisements

Mechanism of Action

Bismatrol Maximum Strength, containing bismuth subsalicylate, exerts its pharmacodynamic effects via multiple, distinct mechanisms within the gastrointestinal lumen. Upon oral administration, the compound hydrolyzes in the gastric environment to form the trivalent bismuth oxychloride and salicylic acid.

The bismuth moiety remains largely localized within the gastrointestinal tract and displays antimicrobial activity. This component binds to the cell walls and membranes of targeted enteric bacteria and fungi, inhibiting their adhesion to mucosal cells and disrupting their energy metabolism, primarily by reducing intracellular ATP. Furthermore, the bismuth forms insoluble salts that coat the intestinal mucosa, providing a protective barrier against irritants.

The salicylate moiety is substantially absorbed and acts as an inhibitor of the cyclooxygenase (COX) enzyme system, specifically COX-1 and COX-2. This inhibition blocks the intracellular synthesis of pro-inflammatory prostaglandins. System-level physiological consequences include modulation of intestinal function: the drug promotes the reabsorption of luminal fluid and electrolytes (sodium and chloride) by the intestinal wall, while simultaneously limiting fluid and electrolyte secretion into the intestinal lumen. These combined intracellular and localized effects modify fluid transport dynamics across the intestinal epithelium.

Advertisements

Dosage and Administration Information

How to Use Bismatrol Maximum Strength

This section describes the administration protocols for Bismuth Subsalicylate, focusing on standardized usage patterns and labeled instructions.


Administration Scope

Parameter Instructions
Route of administration The administration route is Oral.
Dosing schedule (Adults ge 12 years) The standard single dose is 1050 mg, which corresponds to 30 mL of the liquid suspension or two 525 mg caplets.
Frequency pattern Dosing is for as-needed symptomatic use. The 1050 mg dose may be repeated every hour, but the total dose must not exceed 4 doses (4200 mg) within a 24-hour period.
Preparation requirements The Oral Suspension must be shaken well before measurement. Dosing should utilize the measuring device provided with the product for accuracy.
Age-group administration rules Use of this Maximum Strength formulation is restricted for those under 12 years of age; for this population, the instruction is to ask a doctor.

Procedural Context and Duration

The use of this medication is confined to specific procedural conditions. Swallowable Caplets must be taken whole with water, as they are not intended to be chewed. Administration for acute digestive issues is limited to a short duration, requiring discontinuation if symptoms persist more than 2 days. When the medication is used, it is emphasized that there is a requirement to drink plenty of clear fluids to maintain adequate hydration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bismatrol Maximum Strength

Evidence for Use in Acute Diarrhea and Bowel Disruption

This section will summarize the structure of short-term randomized controlled trials and supporting literature that have examined the effect of Bismatrol Maximum Strength on outcomes such as stool frequency and stool consistency in the general patient population.

Research has primarily focused on conditions associated with acute or disruptive episodes, where the drug was studied for outcomes describing episodic or acute changes. These studies typically involved short-term randomized controlled trials (RCTs) in the general patient use population. The research examined outcomes related to the monitoring of physiological strain, specifically stool frequency and stool consistency. The findings describe patterns observed in the studies related to the drug’s physical actions within the digestive tract. Research highlights changes measured during the study period, where trials reported patterns related to stool frequency and consistency.

Evidence for Managing General Stomach Upset and Nausea

This segment will review the regulatory documentation and observational studies that have described the use of Bismatrol Maximum Strength for a cluster of discomforts, including nausea, indigestion, and stomach upset, and describe the types of symptomatic outcomes measured in these reports.

This indication was evaluated in research contexts involving fluctuating or unstable symptoms, where the drug was studied for outcomes related to physical discomfort. Studies focusing on episodes where symptoms become more noticeable examined patient-reported outcomes describing perceived discomfort. Findings describe patterns observed related to physiological strain and reported comfort. Long-term effects are not fully established for repeated use related to this symptom cluster.

Research Gaps and Limited Data in Specific Groups

This content will outline what studies have or have not been conducted regarding the use of Bismatrol Maximum Strength in specific populations, such as children or older adults, and will clarify areas where the evidence may be limited.

The results from the majority of studies apply only to the populations studied in the over-the-counter context. The data for certain groups remain insufficient. For example, limited information is available regarding use in older adults or individuals with multiple comorbidities. The evidence is derived from settings with varying symptom burdens, and subgroup findings are uncertain.

Key Studies & References

  1. DailyMed Label for Bismuth Subsalicylate: Management of Common Digestive Discomforts
  2. Bismuth Subsalicylate Oral Suspension (MedlinePlus) - Symptomatic Treatment of Nonspecific Diarrhea
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bismatrol Maximum Strength (FAQ)

Q: What is Bismatrol Maximum Strength used for?

A: Bismatrol Maximum Strength is an antidiarrheal medication that helps relieve symptoms of an upset stomach. It is used to treat:

  • Diarrhea and travelers' diarrhea
  • Nausea
  • Heartburn
  • Indigestion
  • Gas

Q: Who should not use Bismatrol Maximum Strength?

A: You should not use Bismatrol Maximum Strength if you have:

  • An allergy to bismuth subsalicylate, aspirin, or other salicylate medicines.
  • A stomach ulcer.
  • Bleeding problems or a disorder that causes bleeding easily.
  • Black or bloody stools.

Q: Is there a serious risk when giving this medicine to children or teenagers?

A: Yes. Using medicines that contain salicylates, like Bismatrol Maximum Strength, in a child or teenager who has flu symptoms or chickenpox can cause a serious or fatal condition called Reye's syndrome.

  • Do not give Bismatrol Maximum Strength to children younger than 12 years old without first asking a doctor.

Q: What are the common side effects of Bismatrol Maximum Strength?

A: The most common side effects are usually temporary and may include:

  • Darkening of the tongue (black or grayish-black)
  • Darkening of the stool (grayish-black or black)

These effects are due to the medication interacting with sulfur in the mouth or digestive tract and are not usually harmful. They will go away once you stop taking the medicine.

Q: When should I stop taking Bismatrol Maximum Strength and call a doctor?

A: Stop using this medicine and call your doctor right away if you experience any of the following serious symptoms:

  • Changes in behavior with nausea and vomiting (a possible sign of Reye's syndrome)
  • Hearing loss or ringing or buzzing in your ears (tinnitus)
  • Diarrhea that lasts longer than 2 days or symptoms that get worse
  • Severe or continuing stomach pain
Advertisements

How should Bismatrol Maximum Strength be stored and disposed of?

How to Store and Dispose of Bismatrol Maximum Strength

Official regulatory guidelines define specific conditions for storing and disposing of this medicine (bismuth subsalicylate).


Storage and Handling

Requirement Constraint
Temperature Store at room temperature; avoid temperatures above 104 F (40 C).
Protection The liquid suspension must be protected from freezing. Keep the container tightly closed.
Child Safety Store the medicine out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Bismatrol Maximum Strength via a drug take-back program whenever possible. If a take-back option is unavailable, the product may be discarded in the household trash. When using household trash, the medicine must first be mixed with an undesirable substance (such as coffee grounds or dirt) and placed in a sealed bag or container to deter misuse, as per official FDA guidance. All personal information should be removed from the container prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bismatrol Maximum Strength found in:

A-Z Index: